source
- Dren Bio raises $350 million to advance rare blood cancer antibodyDren Bio, a California biotech, announced a $350 million financing round to fund late‑stage development and commercial preparation of its lead therapy, a CD94‑targeting monoclonal antibody known as…
- BioMarin signs up to $475 million licensing deal for new Fabry disease enzyme therapyBioMarin announced a licensing agreement to acquire rights to a long‑acting enzyme replacement therapy candidate for Fabry disease, paying $70 million upfront and up to $405 million in development…